<https://biotuesdays.com/2022/03/15/transforming-biologic-drug-discovery-with-sean-mcclain-of-absci/>
<http://schema.org/description>
"As CEO and founder of Absci (NASDAQ:ABSI), a drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, Sean McClain has come a long way in the past 10 years. With a vision to revolutionize the way protein-based drugs are developed, Mr. McClain, a biochemist and molecular biologist, founded Absci in a tiny basement lab complete with surplus second-hand equipment. That’s in stark comparison to where Absci, which went public in July 2021, is now: a leader in AI and synthetic biology with more than 200 employees headquartered at its own campus in Vancouver, WA. In this interview with BioTuesdays.com, Mr. McClain discusses how Absci is transforming biologic drug discovery with the benefits of deep learning and synthetic biology."
<https://biotuesdays.com/2022/03/15/transforming-biologic-drug-discovery-with-sean-mcclain-of-absci/>